This white paper explores five common manufacturing and operational challenges that can delay or disrupt the transition from clinical development to commercial production in cell therapy. Designed for professionals involved in bringing cell therapy products to market, the paper provides practical guidance on building scalable, commercially ready manufacturing strategies.
Topics covered include CDMO partner selection, supply chain and logistics management, early commercial planning, cost versus value considerations, and the growing role of automation and digitalization in supporting commercial scale manufacturing. The paper also discusses the increasing importance of manufacturing readiness, process validation, and regulatory planning as more therapies progress toward commercialization.
Developed from insights shared during a recent industry webinar, this white paper highlights practical lessons learned across clinical and commercial programs and outlines strategies to help organizations reduce risk and improve commercialization readiness.
You can also watch the original webinar presentation.
